RxDoctor Payments Data

Brenda Tocket

Psychiatric/Mental Health · Kingston, PANPI 1154908663

Payments from drug & device makers

$3,247in general payments, 2019–2025

Across 179 payments — averaging $18.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$669
  • Alkermes, Inc.$490
  • Otsuka America Pharmaceutical, Inc.$463
  • Teva Pharmaceuticals USA, Inc.$433
  • Johnson & Johnson$287
  • Supernus Pharmaceuticals, Inc.$250
  • plus $654 from 7 others

What the payments were for

  • Food & beverage$3,247100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,247 in reported general payments places this provider in the 85th percentile of 1,041 psychiatric/mental health providers in Pennsylvania.

See all psychiatric/mental health providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$26,029
Medicare patients
79
Services billed
268

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl62$94,095
AristadaAripiprazole Lauroxil19$58,570
Abilify MaintenaAripiprazole19$55,556
Invega SustennaPaliperidone Palmitate14$28,259
LybalviOlanzapine/Samidorphan Malate12$18,875
Aripiprazole285$13,659
Chlorpromazine Hcl89$11,496
Lurasidone Hcl68$9,090
Bupropion XlBupropion Hcl148$9,076
Quetiapine Fumarate528$5,900
Fluoxetine Hcl287$5,847
TrintellixVortioxetine Hydrobromide12$5,519
Olanzapine183$3,624
Buspirone Hcl254$3,409
Clozapine51$3,374

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$669$94,09562 claims
Alkermes, Inc.Aristada, Lybalvi$490$77,44531 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$463$55,55619 claims
Johnson & JohnsonInvega Sustenna$287$28,25914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,041 psychiatric/mental health providers in Pennsylvania.

Other psychiatric/mental health in Kingston

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →